CRISPR-Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial. (nature.com)

Authors: DiPersio JF … Cooper BW Journal: Nature Medicine Published: 2026-05-01 DOI: https://doi.org/10.1038/s41591-026-04362-1